Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Current Alzheimer research
(NYSE: ANVS) (Annovis or the Company), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity) in a mouse model of Alzheimers disease
Urgent treatment should not be delayed when a clinician identifies serious neurological or haematological concerns
This represents one of the highest success rates ever documented for any single intervention in MCAS treatment
US$ 21.93
US$ 24.65
US$ 27.51
US$ 24.73
US$ 23.59
